Français Japonais Chinois Allemand Néerlandais Espagnol Portugais

GSK looks back on successful decade in Hauts-de-France

Gaël Ruche

head of GSK’s plant in Saint-Amand-les-Eaux

Play the video

Major investment in pharmaceutical sector

Ten years ago, GSK earmarked €600 million for a world-class vaccine facility at Saint-Amand-les-Eaux, and today it’s clear that the investment has been a success. The Hauts-de-France site produces 150 million single doses and 100 million multi-packs annually, accounting for 25%-30% of the group’s vaccine output by volume.

Strategic location, strong labor pool

Being close to Lille, Brussels and Paris is a key asset for the Saint-Amand-les-Eaux plant, and its location at a major highway junction delivers smoother, much faster transport.

The facility has a workforce of 800 and GSK has never had trouble recruiting people with the skills it needs, thanks to an industrial history that gives the region a ready supply of qualified workers.

Plans for growth

Since 2015, GSK has invested an additional €13 million at Saint-Amand-les-Eaux, upgrading the facility to step up output and produce a share of the pharmaceutical giant’s new vaccines for shingles and other conditions. And the future looks rosy: now operating at two-thirds of maximum capacity, the Saint-Amand-les-Eaux plant expects a period of growth.